ZELTIQ Aesthetics, Inc., a medical technology company, engages in developing and commercializing non-invasive products for the selective reduction of fat. It offers CoolSculpting system, which utilizes proprietary controlled cooling technology to selectively reduce stubborn fat bulges. ZELTIQ Aesthetics, Inc. sells its products through a direct sales force, as well as through a network of distributors to dermatologists, plastic surgeons, and aesthetic specialists primarily in North America, the Asia-Pacific, Europe, the Middle East, Africa, and Latin America. The company was formerly known as Juniper Medical, Inc. and changed its name to ZELTIQ Aesthetics, Inc. in July 2007. ZELTIQ Aesthetic...
4698 Willow Road
Pleasanton, CA 94588
Founded in 2005
ZELTIQ Aesthetics, Inc. Presents at Goldman Sachs US Emerging & SMID Cap Growth Conference, Nov-19-2015 10:10 AM
Nov 8 15
ZELTIQ Aesthetics, Inc. Presents at Goldman Sachs US Emerging & SMID Cap Growth Conference, Nov-19-2015 10:10 AM. Venue: The Crowne Plaza Times Square, New York, New York, United States.
ZELTIQ Aesthetics, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 10:30 AM
Oct 31 15
ZELTIQ Aesthetics, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 10:30 AM. Venue: Westin Grand Central, New York, New York, United States.
Zeltiq Aesthetics, Inc. Announces Unaudited Consolidated Earnings Guidance for the Third Quarter and Nine Months Ended September 30, 2015; Revises Earnings Guidance for the Full Year 2015
Oct 27 15
ZELTIQ Aesthetics, Inc. announced unaudited consolidated earnings guidance for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported total revenue of $61.2 million compares to $45.7 million for the third quarter 2014. Income from operations was $1.9 million compared to $5.0 million for the third quarter 2014. Income before income taxes was $2,307,000 compared to $4,789,000 for the third quarter 2014. Net income was $2.1 million, or $0.05 per diluted share, compared to $4.8 million for the third quarter 2014, or $0.12 per diluted share. Non-GAAP adjusted EBITDA was $5.6 million, or 9% of revenue, for the third quarter 2015, compared to $7.9 million, or 17% of revenue, for the third quarter 2014.
For the nine months, the company reported revenue of $177,191,000 against $123,706,000 a year ago. Income from operations was $1,895,000 against $518,000 a year ago. Income before income taxes was $1,427,000 against $227,000 a year ago. Net income was $1,196,000 or $0.03 per basic and diluted share against $214,000 or $0.01 per basic and diluted share a year ago. Adjusted EBITDA was $13,868,000 against $8,897,000 a year ago. Net cash provided by operating activities was $5,894,000 against net cash used in operating activities $5,158,000 a year ago. Purchase of property and equipment was $2,332,000 against $1,216,000 a year ago. Purchase of investments was $12,079,000 compared to $9,011,000 a year ago.
For the full year, the company revises revenue guidance of $252 million compared to prior guidance of $245 million to $247 million, and gross profit margin of approximately 71% of total revenue; unchanged from prior guidance. The company expected adjusted EBITDA margin of approximately 9% of total revenue; up from prior guidance of 8% to 9%.